Overcoming the Limitations of Therapeutic Strategies to Combat Pancreatic Cancer using Nanotechnology
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
There is a significant unmet demand for the treatment of pancreatic cancer. Many patients do not make it to past five years after diagnosis. The effectiveness of treatment varies greatly from patient to patient, and many people are too weak to endure chemotherapy or surgery. Unfortunately, by the time patients receive the diagnosis, the tumour typically spreads, rendering these chemotherapies ineffective. Effective anticancer drugs can be better formulated with the help of nanotechnology, which can help them overcome issues with their physicochemical features, such as their poor water solubility or their short half-life in the bloodstream after administration. Many of the reported nanotechnologies offer multifunctional qualities including image guidance and controlled release, in addition to site-specific targeting to the site of action. In this review, we will examine the current status of the most promising nanotechnologies for treating pancreatic cancer, including those still in the research and development phase as well as those that have recently been given the green signal for use in clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Current cancer drug targets - 23(2023), 9 vom: 31., Seite 697-717 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dhoundiyal, Shivang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 06.07.2023 Date Revised 13.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1568009623666230329085618 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355043203 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355043203 | ||
| 003 | DE-627 | ||
| 005 | 20231227131204.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1568009623666230329085618 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM355043203 | ||
| 035 | |a (NLM)36999420 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dhoundiyal, Shivang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Overcoming the Limitations of Therapeutic Strategies to Combat Pancreatic Cancer using Nanotechnology |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a There is a significant unmet demand for the treatment of pancreatic cancer. Many patients do not make it to past five years after diagnosis. The effectiveness of treatment varies greatly from patient to patient, and many people are too weak to endure chemotherapy or surgery. Unfortunately, by the time patients receive the diagnosis, the tumour typically spreads, rendering these chemotherapies ineffective. Effective anticancer drugs can be better formulated with the help of nanotechnology, which can help them overcome issues with their physicochemical features, such as their poor water solubility or their short half-life in the bloodstream after administration. Many of the reported nanotechnologies offer multifunctional qualities including image guidance and controlled release, in addition to site-specific targeting to the site of action. In this review, we will examine the current status of the most promising nanotechnologies for treating pancreatic cancer, including those still in the research and development phase as well as those that have recently been given the green signal for use in clinical practice | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Pancreatic cancer | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a nanotechnology | |
| 650 | 4 | |a photodynamic therapy | |
| 650 | 4 | |a radiotherapy | |
| 650 | 4 | |a tumour microenvironment | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Alam, Md Aftab |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current cancer drug targets |d 2001 |g 23(2023), 9 vom: 31., Seite 697-717 |w (DE-627)NLM120490560 |x 1873-5576 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:9 |g day:31 |g pages:697-717 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1568009623666230329085618 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 9 |b 31 |h 697-717 | ||